"The Walking Dead" versus "Homeland"? That question can actually start a stock-picking discussion, believe it or not.» Read More
Stocks set records despite light volumes, low volatility and low rates. Major averages lift off on modest economic growth.
This bank's "sins" are 6 to 8 years old and the good things are all coming, value investor Bill Smead tells CNBC.
CNBC's Dominic Chu reports the 2 best performing sectors in the S&P 500 this year have been utilities and health care. A quick look at #3, which is energy up 8 percent this year.
CNBC's Michelle Caruso-Cabrera reports on the scandal dominating headlines in the soccer community right now ahead of the World Cup in Brazil.
CNBC's Robert Frank provides a preview of CNBC's next season of "Secret Lives of the Super Rich," including the story of billionaire developer Steve Morgan who still works 80 hours a week.
Pimco's deputy CIO Mark Kiesel, shares some of his firm's top stock picks, including Targa Resources and USG Corp.
Bill Smead, head of his namesake investment firm, tells CNBC that shares of Bank of America could nearly double in five years.
Pimco's deputy CIO Mark Kiesel, discusses his firm's outlook for stocks and bonds right now.
Don't start your trading day without finding out what CNBC's Jim Cramer is watching ahead of the opening bell.
Bill Ackman, founder and CEO of Pershing Square Capital Management, says he wants to help Carl Icahn "find a way out of Herbalife," and why they are friendly again.
Rob Nail, Singularity University CEO, discusses the impact of exponential technologies on finance. Nail says every industry is being impacted by technologies powered by information layers.
Discussing who is vulnerable amid multiple investigations into Herbalife, the company's aggressive buyback, with Bill Ackman, founder and CEO of Pershing Square Capital Management.
Discussing Tyson's win to buy Hillshire Brands, and M&A in the food industry, with B&G Foods CEO David Wenner.
Bill Ackman, founder and CEO of Pershing Square Capital Management, answers why he thinks Valeant's potential takeover of Allergan is beneficial, and the 'unprecedented' terms in the bid.
Discussing "very little" food price pressure for his business, and how the acquisition of brands happens in the food industry, with B&G Foods CEO David Wenner.
CNBC's Steve Liesman provides insight to controversy about jobs data.
Ohio Sen. Rob Portman (R), provides perspective on lower tax rates around the world compared to the U.S., saying the international taxation system needs to be changed.
Merck announced it will buy biotechnology company Idenix for $24.50 per share in cash, with the "Squawk Box" crew.
Discussing the evolution of big pharmaceutical companies, and Valeant's old and new R&D model, with Michael Porter, Harvard Business School professor. Bill Ackman, founder and CEO of Pershing Square Capital Management, weighs in.
Bill Ackman, founder and CEO of Pershing Square Capital Management, discusses James Chanos' short thesis of Valeant Pharmaceuticals.
Get the best of CNBC in your inbox